Literature DB >> 12199489

The burden of chronic obstructive pulmonary disease.

P Vermeire1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a disease state characterized by chronic airflow limitation that is not fully reversible, with a precise definition varying between different management guidelines. The burden of COPD is considerable from all relevant viewpoints. From the perspective of society, the mortality is already considerable, and it is likely to increase from the sixth to the third most common cause of death worldwide by 2020. From the patient's perspective, COPD is responsible for disability that restricts many everyday activities, such as walking up stairs. The burden of COPD on physicians includes increasing consultations for the condition. From the perspective of healthcare payers, COPD represents an increasing burden, primarily due to the costs incurred when exacerbations require hospital treatment. Despite this considerable burden, there are many signs that the impact of COPD is not recognized. Research on COPD is currently underfunded in relation to the impact of the disease; patients only present late with symptoms; physicians may fail to diagnose the condition and healthcare payers may be failing to support treatment approaches that could reduce the number of costly hospital exacerbations. Reasons for this overall poor recognition of the burden of COPD include lack of recognition of the disease, difficulties in diagnosis, poor knowledge of COPD and nihilistic attitudes towards the condition and its treatment. Awareness of COPD could be improved with education of the public and healthcare professionals. Long-term epidemiological studies showing the impact on morbidity and mortality of different treatment approaches would also influence the setting of priorities by healthcare payers.

Entities:  

Mesh:

Year:  2002        PMID: 12199489     DOI: 10.1016/s0954-6111(02)80028-2

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  17 in total

1.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Authors:  Michael Spencer; Andrew H Briggs; Ronald F Grossman; Laureen Rance
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.

Authors:  Claes-Göran Löfdahl; Asa Ericsson; Klas Svensson; Emma Andreasson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  The impact of "World Health Organization - Government of India guidelines on chronic obstructive pulmonary diseases-2003" on quality of life.

Authors:  Ashok K Janmeja; Prasanta R Mohapatra; Mandeep Kumar
Journal:  Lung India       Date:  2009-10

4.  A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Floortje E van Nooten; Marion Lindemann; Manfred Caeser; Peter M A Calverley
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Signs of progress in the Australian post-2000 COPD experience, but some old problems remain.

Authors:  David Dunt; Colleen Doyle
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-06-07

6.  Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease.

Authors:  Linda Timm Wagner; Charlotte A Kenreigh
Journal:  Core Evid       Date:  2005-03-31

7.  Smoking from a Younger Age Is the Dominant Factor in the Incidence of Chronic Obstructive Pulmonary Disease: Case-Control Study.

Authors:  Winda Safitri; Santi Martini; Kurnia Dwi Artanti; Chung-Yi Li
Journal:  Int J Environ Res Public Health       Date:  2021-06-04       Impact factor: 3.390

8.  Patient identified needs for chronic obstructive pulmonary disease versus billed services for care received.

Authors:  Jill Heins-Nesvold; Angeline Carlson; Leslie King-Schultz; Kenneth E Joslyn
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

9.  Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey.

Authors:  Neil Barnes; Peter M A Calverley; Alan Kaplan; Klaus F Rabe
Journal:  BMC Pulm Med       Date:  2013-08-23       Impact factor: 3.317

10.  Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013.

Authors:  Sarah H Landis; Hana Muellerova; David M Mannino; Ana M Menezes; MeiLan K Han; Thys van der Molen; Masakazu Ichinose; Zaurbek Aisanov; Yeon-Mok Oh; Kourtney J Davis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.